1Gedske Daugaard,Niels Rossing,Mikael R?rth. Effects of cisplatin on different measures of glomerular function in the human kidney with special emphasis on high-dose[J] 1988,Cancer Chemotherapy and Pharmacology(2):163～167
2Arlene A. Forastiere,Bonnie J. Takasugi,Shan R. Baker,Gregory T. Wolf,Vickie Kudla-Hatch. High-dose cisplatin in advanced head and neck cancer[J] 1987,Cancer Chemotherapy and Pharmacology(2):155～158
3A. S. Tirelli,N. Colombo,G. Cavanna,C. Mangioni,B. M. Assael. Follow-up study of enzymuria and β 2 microglobulinuria during cis-platinum treatment[J] 1985,European Journal of Clinical Pharmacology(3):313～318
4Joop J. G. Offerman,Sijtze Meijer,Dirk Th. Sleijfer,Nanno H. Mulder,Ab J. M. Donker,Heimen Schraffordt Koops,Gjalt K. Hem. Acute effects of cis-diamminedichloroplatinum (CDDP) on renal function[J] 1984,Cancer Chemotherapy and Pharmacology(1):36～38
3Steinmann P, Walters DK, Arlt MJ, et al. Antimetastatic activityof honokiol in osteosarcoma. Cancer,2012 ,118(8) :2117-2127.
4Sherboume CD, Hays RD, Ordway L, et al. Antecedents ofadherence to medical recommendations : results from the medicaloutcomes study. J Bohav Med, 1992 ,15(5) :447-468.
5Bacci G, Longhi A, Versari M, et al. Prognostic factors forosteosarcoma of the extremity treated with neoadjuvantchemotherapy. Cancer,2006 ,106(5) :1154-1161.
